In summary, at least 11 of the 15 breast cancers from MMR variant carriers showed MMR protein loss, TMB-high or positive PD-L1 expression, suggesting that the majority of breast cancers from MMR variant carriers might benefit from immunotherapy. This evidence concerns the gene CD274 and breast cancer.